Table 3.
Pegylated liposomal doxorubicin + bortezomib combinations in relapsed/refractory setting
| Author | Phase of study | Regimen | Dose | Evaluable pts (#) | PR (%) | CR/nCR (%) | PFS/TTP (med. months) |
|---|---|---|---|---|---|---|---|
| Orlowski22 | I | B-PLD | B 0.9–1.5 mg/m2 d 1, 4, 8, 11 PLD 30 mg/m2 d 4 | 22 | 36 | 36 | 9.3 (TTP) |
| Orlowski22 | III | B vs B-PLD | B 1.3 mg/m2 d 1, 4, 8, 11 ± PLD 30 mg/m2 d 4 | 646 | 41 vs 44 (ORR) | 10 vs 13 | 6.5 vs 9.3 (TTP) 6.5 vs 9.0 (PFS) |
| Chanan-Khan52 | II | B-PLD + T | B 1.3 mg/m2 d 1, 4, 15, 18 PLD 20 mg/m2 d 1, 15 T 200 mg daily | 17 | 42 | 23 (all CR) | 10.9 (PFS) |
| Jakubowiak48 | II | B-PLD + D | B 1.3 mg/m2 d 1, 4, 8, 11 PLD 30 mg/m2 d 4 D 40 mg d 1–4 | 18 | 22 | 33 | N/A |
| Chari53 | I/II | B-PLD + M | B 0.7–1.0 mg/m2 d 1, 4, 8, 11 PLD 10–20 mg/m2 d 1 M 5–10 mg/m2 d 1 | 4 | 0 | 25 | N/A |
Abbreviations: B, bortezomib; D, dexamethasone; M, melphalan; PLD, pegylated liposomal doxorubicin; T, thalidomide; PR, partial response; CR, complete response; nCR, near complete response; ORR, overall response rate; PFS, progression-free survival; TTP, time to disease progression.